This article is more than 5 years old. Information may no longer be current.
Bevacizumab improves vision, reduces macular thickness in pseudophakic CME patients
Click Here to Manage Email Alerts
INDIAN WELLS, Calif. — Administering intravitreal bevacizumab appears effective for treating patients with pseudophakic cystoid macular edema, according to results from the Pan-American Collaborative Retina Study Group presented here.
"Pseudophakic cystoid macular edema (CME) eyes treated by primary Avastin had a vast improvement in visual acuity and macular thickness in this uncontrolled, small-sample-sized study," said Mauricio Maia, MD, at the annual meeting of the American Society of Retina Specialists.
Dr. Maia and colleagues evaluated the efficacy of intravitreal Avastin (bevacizumab, Genentech) in 28 eyes with pseudophakic CME. Regarding dosage, 57% of patients received 1.5-mg injections and 43% received 2.5-mg injections.
Patients averaged 69 years of age and were followed for an average of 32 weeks.
"We observed a fast visual acuity recovery, with the majority of patients recovering their vision within 3 weeks after injection," Dr. Maia said.
Overall, 71% of patients had an improvement in best corrected visual acuity of two or more ETDRS lines. Specifically, average visual acuity improved from logMAR 0.92 at baseline to logMAR 0.5.
No patients lost vision, Dr. Maia noted.
Average central macular thickness improved from 466.3 ?m at baseline to 264.5 ?m at final follow-up. Additionally, researchers observed neither ocular nor systemic adverse events.
"These positive results support further studies with longer follow-up and [with] control eyes," Dr. Maia said.